New biosimilar aims to match phesgo for breast cancer treatment
NCT ID NCT07601620
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a new biosimilar drug, HLX319, works as well as the approved drug Phesgo for people with HER2-positive early or locally advanced breast cancer. About 258 participants will receive either the biosimilar or the original drug before surgery to compare how the drugs move through the body and their safety. The goal is to see if the biosimilar can be a more affordable option without changing effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2 + BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a Triple-Drug attack before surgery eliminate more breast cancer in older women?
- Blood test may reveal if breast cancer treatment is working
- New vaccine combo aims to supercharge immune attack on breast cancer
- New study tests targeted pill combo for advanced breast cancer in Real-World settings
- New drug delivery methods tested for tough breast cancer
- 500 breast cancer patients help scientists crack the code of treatment resistance